Digital Targeted agents and immunotherapies Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment.
News Novartis abandons Fabhalta trial in lupus nephritis A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
